Hu Yaowen, Zhao Jing, Gao Xiaoxing, Xu Yan, Wang Mengzhao
Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
Zhongguo Fei Ai Za Zhi. 2025 Jun 20;28(6):472-476. doi: 10.3779/j.issn.1009-3419.2025.102.25.
Programmed cell death 1 (PD-1) inhibitor therapy for lung adenocarcinoma may induce rare but severe hematologic adverse events, including severe anemia. Although glucocorticoids are recommended for managing immune-related adverse events, therapeutic experience with PD-1 inhibitor-induced severe anemia remains limited, and its efficacy and safety have not been fully validated. This article reports a case of advanced lung adenocarcinoma in which severe anemia developed following combination therapy with chemotherapy and PD-1 inhibitor. After comprehensive evaluation, the patient was diagnosed with anemia of inflammation (AI) and achieved significant hemoglobin recovery following high-dose glucocorticoid treatment. These findings may provide new insights into the recognition and management of this rare hematologic toxicity in clinical practice. .
程序性细胞死亡蛋白1（PD-1）抑制剂治疗肺腺癌可能会引发罕见但严重的血液学不良事件，包括严重贫血。尽管推荐使用糖皮质激素来处理免疫相关不良事件，但PD-1抑制剂诱发严重贫血的治疗经验仍然有限，其疗效和安全性尚未得到充分验证。本文报告了1例晚期肺腺癌患者，该患者在化疗联合PD-1抑制剂治疗后出现严重贫血。经过全面评估，患者被诊断为炎症性贫血（AI），并在大剂量糖皮质激素治疗后血红蛋白显著恢复。这些发现可能为临床实践中识别和处理这种罕见的血液学毒性提供新的见解。
